X-Therma Achieves GMP Commercial Readiness with XT-Thrive®
XT-Thrive® enables non-toxic cryopreservation for life-saving regenerative medicines such as vaccines, cell lines for production, cell and gene therapies, and engineered tissues. The DMSO-free, serum-free, protein-free, and chemically defined cryopreservation media is designed to significantly enhance the preservation of biological materials, offering unprecedented efficiency and reliability.
"This announcement marks a critical step forward in ensuring the highest quality and scalability of XT-Thrive® for widespread clinical and commercial applications," said
In
"With GMP commercial readiness, XT-Thrive® will meet the stringent quality and regulatory standards required for clinical use, positioning X-Therma as a key player in the biopreservation market," said
X-Therma has established an independent quality organization and a robust Quality Management System (QMS) that meets
X-Therma will be available to discuss this news at upcoming conferences including:
May 29-June 1, 2024 : ISCT 2024 inVancouver , Booth #646June 1-5, 2024 : American Transplant Congress inPhiladelphia , Booth #630June 3-6, 2024 : Biotechnology Innovation Organization (BIO) International Convention in San Diego. X-Therma is scheduling meetings through the BIO One-on-One Partnering™ system.
About X-Therma Inc.
X-Therma Inc. is pioneering breakthrough cold chain technology via a convergent biopreservation platform, to advance regenerative medicine and make available safe and on-demand organs, engineered tissues, cell and gene therapies, vaccines, and beyond to patients in need. Headquartered in Hercules, part of the San Francisco Bay Area and an expanding presence in Austria, X-Therma's technology is poised to become a paradigm shift that enables worldwide organ sharing and eliminates organ waiting lists across the globe.
About XT-Thrive®
XT-Thrive® is a DMSO-free, serum-free, protein-free, and chemically defined cryopreservation media enabling the preservation of mammalian cells at ultra-low temperatures (-70° C to -196° C). It incorporates a fundamentally new class of cryoprotectant, named peptoids, fully synthetic defined molecules are inspired by natural antifreeze proteins (hyper-effective and non-toxic) to prevent aberrant ice formation and risk of shock-induced ice damage. This product can be used for the cryopreservation of cells used for manufacture of biological products including monoclonal antibodies, recombinant proteins, fusion proteins, and vaccines. XT-Thrive® does not require a manual wash-out step, thus elevating its safety profile in comparison to other cryopreservation media.
View original content to download multimedia:https://www.prnewswire.com/news-releases/x-therma-achieves-gmp-commercial-readiness-with-xt-thrive-302158025.html
SOURCE X-Therma Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SoCalGas Board of Directors Approves Retirement of All Outstanding Shares of Preferred Stock
- Texas de Brazil & Customers Donate More Than $25,000 to the American Red Cross
- TORM PLC - Major Shareholder Announcement
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share